Related Experiment Video
Updated: Jul 4, 2026

A Fluorogenic Peptide Cleavage Assay to Screen for Proteolytic Activity: Applications for coronavirus spike protein activation
Published on: January 9, 2019
Structure of the main protease from a global infectious human coronavirus, HCoV-HKU1
1Tsinghua-Nankai-IBP Joint Research Group for Structural Biology, Tsinghua University, Beijing, China.
Insights
Researchers determined the structure of the human coronavirus HKU1 main protease (M(pro)) complexed with an inhibitor. This provides insights for developing new antiviral drugs targeting coronaviruses.
Area of Science:
- Virology
- Structural Biology
- Drug Discovery
Background:
- Human coronavirus HKU1 (HCoV-HKU1) is an emergent virus causing respiratory illnesses globally.
- The coronavirus main protease (M(pro)) is crucial for viral replication and a target for antiviral development.
Purpose of the Study:
- To determine the three-dimensional structure of the HCoV-HKU1 M(pro) in complex with a Michael acceptor inhibitor (N3).
- To provide a structural basis for understanding HCoV-HKU1 M(pro) function and for designing novel antiviral agents.
Main Methods:
- X-ray crystallography was used to determine the structure of the HCoV-HKU1 M(pro)-inhibitor N3 complex.
- Genome sequencing of HCoV-HKU1 was performed to analyze sequence conservation.
- Activity assays were conducted to assess enzyme function.
Main Results:
- The study reports the high-resolution crystal structure of HCoV-HKU1 M(pro) bound to inhibitor N3.
- Structural analysis revealed conserved features at the P1 position, consistent with genomic sequencing data.
- The structure serves as a model for group 2A CoVs, distinct from group 2B CoVs like SARS-CoV.
Conclusions:
- The determined HCoV-HKU1 M(pro) structure offers valuable insights into substrate specificity.
- This structural information aids in the rational design of broad-spectrum antivirals targeting M(pro) across different coronaviruses.
Abstract:
The newly emergent human coronavirus HKU1 (HCoV-HKU1) was first identified in Hong Kong in 2005. Infection by HCoV-HKU1 occurs worldwide and causes syndromes such as the common cold, bronchitis, and pneumonia. The CoV main protease (M(pro)), which is a key enzyme in viral replication via the proteolytic processing of the replicase polyproteins, has been recognized as an attractive target for rational drug design. In this study, we report the structure of HCoV-HKU1 M(pro) in complex with a Michael acceptor, inhibitor N3. The structure of HCoV-HKU1 provides a high-quality model for group 2A CoVs, which are distinct from group 2B CoVs such as severe acute respiratory syndrome CoV. The structure, together with activity assays, supports the relative conservation at the P1 position that was discovered by sequencing the HCoV-HKU1 genome. Combined with structural data from other CoV M(pro)s, the HCoV-HKU1 M(pro) structure reported here provides insights into both substrate preference and the design of antivirals targeting CoVs.
Related Concept Videos
Coronavirus
Viral Structure
The Proteasome Structure
The proteasome is an...
Inhibitors of Virion Maturation and Assembly
Protein Complex Assembly
Many viruses self-assemble into a fully functional unit using the infected host cell to...
Leaky Scanning

